- QMRO Home
- Barts Cancer Institute
- Centre for Haemato-Oncology
- THE ADDITION OF RITUXIMAB TO CODOX-M/IVAC CHEMOTHERAPY IN THE TREATMENT OF BURKITT LYMPHOMA IS SAFE AND IS ASSOCIATED WITH INCREASED EFFICACY IN THE HIV POSITIVE POPULATION
Browse
Administrators only